Luiza Madia Lourenco1, Yanyan Jiang1, Neele Drobnitzky1, Marcus Green1, Fiona Cahill1, Agata Patel1, Yasmin Shanneik1, John Moore1, Anderson J Ryan2. 1. Cancer Research UK and UK Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. 2. Cancer Research UK and UK Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. Electronic address: anderson.ryan@oncology.ox.ac.uk.
Abstract
PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to enhance the radiosensitivity of cancer cells in vitro in a replication-dependent manner. Their in vivo radiosensitizing effects have also been demonstrated in preclinical tumor models. However, whether PARP inhibition can enhance the response to radiation therapy in normal tissues has been largely neglected. We hypothesized that PARP inhibition might also potentiate the response of replicating normal tissues to radiation therapy. In this study, we examined the normal tissue response in mice treated with PARP inhibitors (BMN673 or AZD2281) in combination with thoracic irradiation. METHODS AND MATERIALS: The antitumor effects of fractionated irradiation (5 Gy × 4) in combination with BMN673 were evaluated in nude mice bearing established Calu-6 human lung cancer xenografts. The normal tissue response was evaluated in C57BL6 mice that were treated with BMN673 or AZD2281 combined with fractionated irradiation, 5 Gy × 4, delivered to the whole thorax. Body weight and histology of the esophagus and skin in the field of irradiation were examined. The DNA damage response in the esophagus and skin was assessed by γH2AX immunohistochemistry. RESULTS: While PARP inhibition enhanced irradiation-induced tumor growth inhibition in nude mice, it was also associated with significant body weight loss and increased damage to the esophagus and skin within the field of irradiation in C57BL6 mice. PARP inhibition compromised the repair of irradiation-induced DNA damage in the esophagus and skin. CONCLUSIONS: Although PARP inhibition enhanced the antitumor response to fractionated irradiation, it also enhanced the irradiation response in replicating normal tissues. Therefore, our study suggests that additional caution may be warranted in the clinical development of combination therapies using PARP inhibitors and radiation therapy, in particular where the field of irradiation includes the esophagus.
PURPOSE:Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to enhance the radiosensitivity of cancer cells in vitro in a replication-dependent manner. Their in vivo radiosensitizing effects have also been demonstrated in preclinical tumor models. However, whether PARP inhibition can enhance the response to radiation therapy in normal tissues has been largely neglected. We hypothesized that PARP inhibition might also potentiate the response of replicating normal tissues to radiation therapy. In this study, we examined the normal tissue response in mice treated with PARP inhibitors (BMN673 or AZD2281) in combination with thoracic irradiation. METHODS AND MATERIALS: The antitumor effects of fractionated irradiation (5 Gy × 4) in combination with BMN673 were evaluated in nude mice bearing established Calu-6 humanlung cancer xenografts. The normal tissue response was evaluated in C57BL6 mice that were treated with BMN673 or AZD2281 combined with fractionated irradiation, 5 Gy × 4, delivered to the whole thorax. Body weight and histology of the esophagus and skin in the field of irradiation were examined. The DNA damage response in the esophagus and skin was assessed by γH2AX immunohistochemistry. RESULTS: While PARP inhibition enhanced irradiation-induced tumor growth inhibition in nude mice, it was also associated with significant body weight loss and increased damage to the esophagus and skin within the field of irradiation in C57BL6 mice. PARP inhibition compromised the repair of irradiation-induced DNA damage in the esophagus and skin. CONCLUSIONS: Although PARP inhibition enhanced the antitumor response to fractionated irradiation, it also enhanced the irradiation response in replicating normal tissues. Therefore, our study suggests that additional caution may be warranted in the clinical development of combination therapies using PARP inhibitors and radiation therapy, in particular where the field of irradiation includes the esophagus.
Authors: Saif S Ahmad; Marka R Crittenden; Phuoc T Tran; Paul G Kluetz; Gideon M Blumenthal; Helen Bulbeck; Richard D Baird; Kaye J Williams; Tim Illidge; Stephen M Hahn; Theodore S Lawrence; Patricia A Spears; Amanda J Walker; Ricky A Sharma Journal: Clin Cancer Res Date: 2018-11-29 Impact factor: 12.531
Authors: Sana D Karam; Krishna Reddy; Patrick J Blatchford; Tim Waxweiler; Alicia M DeLouize; Ayman Oweida; Hilary Somerset; Carrie Marshall; Christian Young; Kurtis D Davies; Madeleine Kane; Aik Choo Tan; Xiao Jing Wang; Antonio Jimeno; Dara L Aisner; Daniel W Bowles; David Raben Journal: Clin Cancer Res Date: 2018-07-03 Impact factor: 12.531
Authors: Salma K Jabbour; Terence M Williams; Mutlay Sayan; Eric D Miller; Jaffer A Ajani; Andrew C Chang; Norman Coleman; Wael El-Rifai; Michael Haddock; David Ilson; Daniel Jamorabo; Charles Kunos; Steven Lin; Geoffrey Liu; Pataje G Prasanna; Anil K Rustgi; Rosemary Wong; Bhadrasain Vikram; Mansoor M Ahmed Journal: J Natl Cancer Inst Date: 2021-06-01 Impact factor: 13.506
Authors: Yanyan Jiang; Jennifer Martin; Maryam Alkadhimi; Kay Shigemori; Paul Kinchesh; Stuart Gilchrist; Veerle Kersemans; Sean Smart; James M Thompson; Mark A Hill; Mark J O'Connor; Barry R Davies; Anderson J Ryan Journal: Br J Cancer Date: 2021-03-19 Impact factor: 7.640
Authors: R de Haan; E van Werkhoven; M M van den Heuvel; H M U Peulen; G S Sonke; P Elkhuizen; M W M van den Brekel; M E T Tesselaar; C Vens; J H M Schellens; B van Triest; M Verheij Journal: BMC Cancer Date: 2019-09-10 Impact factor: 4.430
Authors: Catherine E Willoughby; Yanyan Jiang; Huw D Thomas; Elaine Willmore; Suzanne Kyle; Anita Wittner; Nicole Phillips; Yan Zhao; Susan J Tudhope; Lisa Prendergast; Gesa Junge; Luiza Madia Lourenco; M Raymond V Finlay; Paul Turner; Joanne M Munck; Roger J Griffin; Tommy Rennison; James Pickles; Celine Cano; David R Newell; Helen L Reeves; Anderson J Ryan; Stephen R Wedge Journal: J Clin Invest Date: 2020-01-02 Impact factor: 14.808